Search
NRX Pharmaceuticals Inc
NRXPAdd to Watchlist
3.870USD
+0.010+0.26%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
140.21MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.26%
5 Days
+8.71%
1 Month
-16.23%
6 Months
+47.71%
Year to Date
+42.80%
1 Year
+16.57%
Key Figures
3.910Open
3.990High
668.70KVolume
LossP/E TTM
1.31P/E Dynamic
--Dividend TTM
1.86%Turnover Ratio
3.860Prev. Close
3.795Low
1.87MTurnover
LossP/E Static
-10.03P/B
0.00%Div Yield TTM
-251.78%ROA
5.05552wk High
0.50Volume Ratio
-25.13MNet Profit
33.47MShares
-1.0457EPS TTM
2.12Beta
-682.81%ROE
1.62052wk Low
6.25%Amplitude
35.02%Gross Margin
140.21MMarket Cap
-1.84Reward/Risk
5.17%Risk Rate
TradingKey Stock Score of NRX Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
NRX Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 123 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 40.40.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NRX Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
NRX Pharmaceuticals Inc Highlights
StrengthsRisks
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.23M.
Fairly Valued
The company’s latest PE is -3.70, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.80M shares, increasing 34.18% quarter-over-quarter.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
40.400
Target Price
+910.00%
Upside Space
NRX Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NRX Pharmaceuticals Inc Info
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Ticker SymbolNRXP
CompanyNRX Pharmaceuticals Inc
CEOJavitt (Jonathan C)
Websitehttps://www.nrxpharma.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
53006.200
+163.700 (+0.31%)
29619.300
+307.900 (+1.05%)
7513.300
+41.800 (+0.56%)
15014.000
+211.000 (+1.43%)
69820.000
+1672.000 (+2.45%)
6389.500
+36.700 (+0.58%)
68.853
+0.509 (+0.74%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4172.090
+50.180 (+1.22%)
FAQs
What is the current price of NRX Pharmaceuticals Inc (NRXP)?
The current price of NRX Pharmaceuticals Inc (NRXP) is 3.87.
What is the symbol of NRX Pharmaceuticals Inc?
The ticker symbol of NRX Pharmaceuticals Inc is NRXP.
What is the 52-week high of NRX Pharmaceuticals Inc?
The 52-week high of NRX Pharmaceuticals Inc is 5.05.
What is the 52-week low of NRX Pharmaceuticals Inc?
The 52-week low of NRX Pharmaceuticals Inc is 1.62.
What is the market capitalization of NRX Pharmaceuticals Inc?
The market capitalization of NRX Pharmaceuticals Inc is 129.53M.
Is NRX Pharmaceuticals Inc (NRXP) currently rated as Buy, Hold, or Sell?
According to analysts, NRX Pharmaceuticals Inc (NRXP) has an overall rating of Buy, with a price target of 40.40.
What is the Earnings Per Share (EPS TTM) of NRX Pharmaceuticals Inc (NRXP)?
The Earnings Per Share (EPS TTM) of NRX Pharmaceuticals Inc (NRXP) is -1.34.